RTP Mobile Logo
Second Opinion: Case-Based Discussion on the Management of Patients with Early and Advanced Breast Cancer
Released April 2012

A special audio supplement to a CME conference held during the 2011 San Antonio Breast Cancer Symposium featuring expert comments by Dr George W Sledge Jr on key new data sets presented. (Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY

    Breast cancer is one of the most rapidly evolving fields in medical oncology. Results from numerous ongoing trials lead to the continual emergence of new therapeutic agents, treatment strategies and diagnostic and prognostic tools. To bridge the gap between research and patient care, this case-based CME activity features expert perspective on the latest research developments presented at the 2011 San Antonio Breast Cancer Symposium and discussion of relevant clinical issues to assist medical oncologists, hematologists/oncologists and hematology-oncology fellows in the formulation of up-to-date clinical management strategies.

    LEARNING OBJECTIVES

    • Integrate validated genomic assays into the clinical management of estrogen receptor (ER)-positive, node-negative and node-positive early breast cancer.
    • Assimilate new clinical trial evidence into the therapeutic algorithm for advanced ER-positive breast cancer.
    • Appraise the role of bone-directed systemic treatment in the management of breast cancer.
    • Demonstrate knowledge of emerging research to support alternative or novel chemotherapeutic regimens in the adjuvant and metastatic settings, and integrate these findings into best-practice disease management strategies.
    • Apply the results of emerging research to effectively integrate HER2-directed treatments into the systemic management of advanced HER2-positive breast cancer.
    • Recognize the rationale for ongoing investigation of angiogenesis inhibitors in the adjuvant setting.
    • Recall the results of pivotal trials introducing effective new breast cancer therapeutics, and identify their impact on existing treatment algorithms.

    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY

    This CME activity contains an audio component. The participant should review the CME information and listen to the audio MP3s.

    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTYDr Sledge had no real or apparent conflicts of interest to disclose.

    MODERATOR Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Lilly USA LLC,  Medivation Inc, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Celgene Corporation, Genentech BioOncology, Genomic Health Inc and Novartis Pharmaceuticals Corporation.

    Hardware/Software Requirements:

    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date:
    April 2012
    Expiration date: April 2013

Acknowledge and close

Listen to audio:
Second Opinion: Case-Based Discussion on the Management of Patients with Early and Advanced Breast Cancer
Released April 2012

A special audio supplement to a CME conference held during the 2011 San Antonio Breast Cancer Symposium featuring expert comments by Dr George W Sledge Jr on key new data sets presented. (Audio Content)

Read print: